title: Effects of fluosol-DA on brain edema, energy metabolites, and tissue oxygen content in acute cerebral ischemia.
abstract: Perfluorochemicals were developed as a blood substitute and were reported to have an advantage in oxygen transport compared with blood. The present study was undertaken to investigate the therapeutic effects of a perfluorochemical, FDA, on brain edema and metabolites in acute cerebral ischemia. Cerebral ischemia was induced in SHR by BLCO followed by recirculation. The FDA administration resulted in (a) the significant inhibition of brain edema as shown by brain water content in the treated group, and (b) significant amelioration of metabolic impairments as shown by lesser degree of ATP and pyruvate decrease and lactate accumulation. The TpO2 was compared between FDA-infused and nontreated group during ischemia. The FDA-infused group had significantly higher TpO2 than nontreated group. These results indicate that the improvement of brain edema and metabolite levels were due to alleviation of ischemic hypoxia by FDA under the same ischemic insult.
authors.affiliation: Second Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Memezawa
authors.forename: Y
authors.initials: Y
authors.lastname: Katayama
authors.forename: J
authors.initials: J
authors.lastname: Shimizu
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: F
authors.initials: F
authors.lastname: Kashiwagi
authors.forename: T
authors.initials: T
authors.lastname: Kamiya
authors.forename: A
authors.initials: A
authors.lastname: Terashi
mesh_terms: D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects*; D001929:Brain Edema / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D002545:Brain Ischemia / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D002245:Carbon Dioxide / Q000097:blood; D004338:Drug Combinations / Q000494:pharmacology / Q000627:therapeutic use; D004734:Energy Metabolism / Q000187:drug effects; D005466:Fluorocarbons / Q000494:pharmacology / Q000627:therapeutic use*; D006400:Hematocrit; D006895:Hydroxyethyl Starch Derivatives; D006973:Hypertension / Q000150:complications; D000860:Hypoxia / Q000517:prevention & control; D008297:Male; D010100:Oxygen / Q000378:metabolism*; D010313:Partial Pressure; D051381:Rats; D011918:Rats, Inbred SHR
chemical_list: D004338:Drug Combinations; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; D002245:Carbon Dioxide; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; D010100:Oxygen